CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy comp...
ImmunityBio (NASDAQ:IBRX) Shares Down 6.3% - What's Next?...
HC Wainwright restated a "buy" rating and issued a $8.00 target price on shares of ImmunityBio in a ...
The post ASCO 2025 Annual Meeting appeared first on ImmunityBio. ASCO Annual Meeting 2025 Date: May ...
ImmunityBio (NASDAQ:IBRX) Shares Gap Up - Here's Why...